Navigation Links
Lumenis(R) Seeks Shareholder Approval of Proposed Class Action Settlement
Date:2/11/2008

YOKNEAM, Israel, Feb. 11 /PRNewswire/ -- Lumenis(R) Ltd. announced today that it has scheduled a special general meeting of shareholders to seek approval and authorization, in accordance with the Israeli Companies Law, of a proposed settlement of the securities class action litigation that has been pending against the Company in the federal court in New York since 2002. Under the terms of the proposed settlement, which has been agreed to in principle by Lumenis and the lead plaintiffs on behalf of the class, a total of $20.1 million would be contributed to a settlement fund for the benefit of the class. While Lumenis itself would contribute a portion of this fund, the major portion would be paid on behalf of the defendants by the Company's insurers.

Assuming shareholder approval is forthcoming, the settlement will still be subject to a number of conditions, including the execution and preliminary court approval of a definitive stipulation of settlement, and final court approval after there has been notice to the members of the class and a hearing as to the fairness of the proposed settlement. If the settlement is finally approved by the court, the class action litigation will be dismissed with prejudice against Lumenis and the former Lumenis officers and directors who have been named as defendants.

About Lumenis Ltd.

Lumenis is Israel's largest medical device company with more than 1,000 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems. In December 2006, a group led by a private equity consortium LM Partners LP and Ofer Hi-Tech Group invested approximately $150 million in the Company.

Contact:

Michelle Maydan

Director of Corporate Communications

1-866-569-0597

+972-4-959-9004

e
'/>"/>

SOURCE Lumenis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Lumenis(R) Introduces the Newest Innovations in Fractional CO2 Laser Skin Therapy
2. Mayo Clinic Seeks Mitigation for Rochester as Condition of Canadian Pacific - DM&E Railroad Merger
3. URAC Seeks Public Comment on Standards for New Pharmacy Accreditation Programs
4. NIH panel seeks to dispel stigma associated with fecal and urinary incontinence
5. Group Seeks Refinement of Knee Arthritis Treatment Guidelines
6. The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off States Existing Six-Year Surcharge Period
7. Leading neuroscientist seeks beauty, love and happiness
8. American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants
9. FDA Seeks Food Recall Authority
10. Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages
11. New Legislation Seeks to Improve Access to Community Mental Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...s supporting the US Department of Defense and Fede...n Phoenix. Operation Golden Phoenix is a, four-d...gned to assist, federal, state and local agencies ...ios. Dataline is providing a vital, ad-hoc, secure...l use during the exercise., NORFOLK, Va., July 25...
(Date:7/25/2008)...Relationship Based on Significant Improvements in ... MDdatacor, Inc., a leader in health,care quality ...s, today,announced it has entered into a long-term...ort Wellmark,s Collaboration on Quality(SM) Incent...tion between Wellmark and,primary care clinicians ...
(Date:7/25/2008)...BURG, Ill., July 25 /PRNewswire/ -- Sagent Pharmac...eutical company, today announced that it,has launc...iarrhythmic,indicated for the treatment and prophy...tion and hemodynamically unstable ventricular,tach...r heart beat.,Sagent,s amiodarone HCl injection wi...
(Date:7/25/2008)...to benefit ALS Therapy Alliance to be presented at...t, WOONSOCKET, R.I., July 25 /PRNewswire/ -- CVS/...sed a record-breaking $4.4 million in just 21 days...for ALS research. This is,the seventh year of the ...ed more than $15 million for ALS research. This ye...
Breaking Medicine News(10 mins):Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2
...ventricular ectopy, another name for premature hea...ound by researchers to be a better predictor of an...g exercise. Doctors from Cleveland Clinic Foundati...eart failure, valve disease or arrhythmia. They we...
...survey by the American Society of Plastic Surgeons...out their appearance, as women. They found that li...ular procedures preferred by men. More than two t...out what they would like to change about their app...
...urysm is a weakness in one of the blood vessels in...y resulting in a brain hemorrhage. Around thirty t...emorrhage in a year and they are treated surgicall... neck of the bulge. A bulge with a narrow neck is ...
... its "purest" form has no fat and no calories what...ke cream and flavoured syrup can add on to calorie...chocolate or blended coffee drinks can add up to 5...-ons and their effects on your waistline. Two tabl...
Other Medicine News:Health News:A cup of coffee could hamper your diet 2
(Date:7/23/2008)...ASPS Study Finds Some Areas of the Body Have Great...S, Ill., July 23 /PRNewswire-USNewswire/ -- Fat re...gh liposuction was found to be,an excellent source...ns,than other areas of the body, reports a Brazili...ive Surgery(R), the official medical journal of th...
(Date:7/22/2008)...BRISBANE, Australia, July 22 /PRNewswire-FirstCall...te yesterday, the Board of Progen,Pharmaceuticals ...hat it,had discontinued the PI-88 phase 3 study in...ction to develop its existing portfolio of compoun...dditional compounds and,opportunities through Merg...
(Date:7/22/2008)... FDA Meeting to Discuss Development Plan Complet...wire-FirstCall/ -- Amarin Corporation,plc (NASDAQ:... met with,officials at the U.S. Food and Drug Admi... develop AMR101 for the treatment of,hypertriglyce...is,proceeding to Phase 3 with AMR101 in hypertrigl...
(Date:7/22/2008)...EO Geoffrey Allan Will Stress the Importance to Pa...logics Approval Pathway, RICHMOND, Va., July 22 /...NSM) a developer of follow-on biologics and biopha... Ph.D., CEO of Insmed, will present at a,Congressi...s the,significant need for establishing an approva...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3FDA Advisory Committee Unanimously Recommends U S Approval of Sugammadex the First and Only Selective Relaxant Binding Agent 1504 1FDA Advisory Committee Unanimously Recommends U S Approval of Sugammadex the First and Only Selective Relaxant Binding Agent 1504 2FDA Advisory Committee Unanimously Recommends U S Approval of Sugammadex the First and Only Selective Relaxant Binding Agent 1504 3FDA Advisory Committee Unanimously Recommends U S Approval of Sugammadex the First and Only Selective Relaxant Binding Agent 1504 4WellPoint Announces Appearances at Upcoming Conferences 14092 1WellPoint Announces Appearances at Upcoming Conferences 14092 2Robbins 26 Myers Schedules Second Quarter Fiscal 2008 Financial Results Conference Call 14090 1Post Op Chemo Fails to Boost Survival in Stomach Cancers 14089 1Post Op Chemo Fails to Boost Survival in Stomach Cancers 14089 2
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments.
Liquichek Qualitative Urine Toxicology Control is a liquid control designed for use with qualitative rapid urine drug screen panels, including Point of Care (POC) Drugs of Abuse (DOA) test kits like
Liquichek Sedimentation Rate Control is a bilevel human whole blood based control designed to monitor both manual and automated methods for measuring erythrocyte sedimentation rates.
Liquichek Hematology-16 Control is specifically designed for use on most hematology analyzers that measure up to 16 parameters and 3-part white blood cell differentials. This trilevel control can be
Medicine Products: